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Introduction 
Ovarian cancer is the fifth leading cause of cancer-
related deaths among women in Europe and the 
United States of America, and is the most frequent 
cause of death among all gynaecological cancers 
in Europe (Ferlay et al., 2018; American Cancer 
Society, 2020a). In 2018, ovarian cancer accounted 
for 3.7% of all new cancer cases in women in 
Europe (Ferlay et al., 2018). In Belgium, 752 new 
cases of ovarian cancer were diagnosed in 2016 
(Belgian Cancer Registry, 2016).
Ovarian cancer is often asymptomatic, resulting 
in diagnosis at advanced stages in most patients. 
This trend is reflected in the Belgian cancer 
statistics from 2016; 18.9%, 5.6%, 28.7%, and 
25.1% of ovarian cancer patients were diagnosed 
with stage I,II, III, and IV disease, respectively 
(21.6% of patients had an unreported stage) 
(Belgian Cancer Registry, 2016). In Belgium, 
the five-year relative survival rate (2012‒2016) 
was 78.0% (95% confidence interval [CI]: 72.0–
83.0) in 15- to 44-year-old patients, 52.9% (95% 
CI: 50.0–55.8) in 45- to 69-year-old patients, 
and 27.9% (95% CI: 24.8–31.1) in ≥70-year-old 
patients (Belgian Cancer Registry, 2016). Survival 
outcomes are worse in the elderly and patients 
with advanced-stage ovarian cancer at the time of 
diagnosis. Patients diagnosed with stage I disease 
had a five-year relative survival rate of 91.0% 
(survival data in Belgium, 2004–2008) (Belgian 
Cancer Registry, 2012). In comparison, this rate 
was only 19.1% among women with stage IV 
disease at diagnosis.
Treatment algorithm in patients with ovarian cancer
I. Vergote1, H. Denys2, J. De greVe3, C. gennIgens4, K. Van De VIJVer5,6, J. Kerger7, P. VuylsteKe8, 
J.F. BauraIn8,9 
1Department of Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium; 2Department of Medical 
Oncology, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium; 3Department of Medical Genetics, 
University Hospitals Brussels, Laarbeeklaan 101, 1090, Brussels, Belgium; 4Department of Medical Oncology, Liège 
University Hospital, Avenue de l’Hôpital 1, 4000 Liège, Belgium; 5Department of Pathology, Ghent University Hospital, 
C. Heymanslaan 10, 9000 Ghent, Belgium; 6Department of Pathological Anatomy, Antwerp University Hospital, 
Universiteitsplein 1, 2610 Wilrijk, Belgium; 7Jules Bordet Institute, Brussels University Hospital,Boulevard de Waterloo 
121, 1000 Brussels, Belgium; 8Department of Oncology, UCLouvain, CHU UCL Namur Hospital, Site St-Elisabeth, 
Place Louise Godin 15, 5000 Namur, Belgium; 9Department of Oncology, St.-Luc University Hospital Brussels,Avenue 
Hippocrate 10, 1200 Woluwe-Saint-Lambert, Belgium.
Correspondence at: : Ignace Vergote, Department of Oncology, University Hospitals Leuven,Herestraat 49, 3000 
Leuven, Belgium, e-mail: ignace.vergote@uzleuven.be
Abstract
Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, and 
when therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancer 
includes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted and 
antiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovarian 
cancer subtypes and stages has increased considerably. This has enabled the development and improvement of 
several options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly, 
therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecular 
features of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing of 
germline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In order 
to implement the best individual medical strategies, in this article, we present an algorithm of treatment options, 
including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.
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Here, we aim to provide an overview of the current 
treatment landscape for ovarian cancer in Belgium to 
help physicians translate evidence and guidelines into 
individualised medical strategies for their patients.
Histological and molecular features of ovarian 
cancer 
Ovarian cancer is a heterogeneous disease: it is 
comprised of tumours that can show very different 
morphologies, histologies, grades, and molecular 
characteristics (Lheureux et al., 2019). Epithelial 
ovarian cancer (EOC) represents approximately 
90% of these malignant tumours, whereas sex-cord 
stromal, germ cell, and mixed-cell ovarian cancers 
account for the remaining 10% (Hanby et al., 2003; 
Rojas et al., 2016).
The term “EOC” does not refer to a single disease 
but encompasses a group of tumours. According to 
their morphology, several histological subtypes of 
EOC have been defined, with the most common being 
the serous (68%–71%) subtype, followed by clear 
cell (12%–13%), endometrioid (9%–11%), mucinous 
(3%), malignant Brenner (1%) and mixed histology 
(6%) subtypes (Rojas et al., 2016). In a more recent 
classification, EOCs were divided into five types 
based on histopathology, immunohistochemistry, 
and molecular genetic analysis: high-grade serous 
carcinomas (HGSC; approximately 70%), low-grade 
serous carcinomas (LGSC; 10%), endometrioid 
carcinomas (approximately 10%), clear cell 
carcinomas (approximately 5%), and mucinous 
carcinomas (<3%) ( Lheureux et al., 2019).The 
five types of EOC have a distinct tumour biology, 
which directly affects their prognosis and outcome 
(Lheureux et al., 2019). Predictive biomarkers 
(histology and molecular genomics) have been 
recently identified for each type of EOC (Table I) 
(Lheureux et al., 2019). Molecular criteria may 
provide insight for therapy selection by stratifying 
low-grade diseases into separate clusters; however, 
the high-grade disease is less genetically defined 
(Hirst et al., 2017).
Ovarian cancers are staged surgically and 
pathologically according to two systems: the 
International Union Against Cancer (UICC) TNM 
(tumor, node, and metastasis) system of classification 
of malignant tumours, and the International 
Federation of Gynecology and Obstetrics (FIGO) 
staging system (Prat and FIGO Committee on 
Gynecologic Oncology, 2014; Brierley et al., 2017). 
FIGO stages are defined by the confinement of the 
tumour to the ovaries or fallopian tubes (stage I), the 
involvement of ovaries or fallopian tubes with pelvic 
extension or primary peritoneal cancer (stage II), the 
additional cytologically or histologically confirmed 
spread of the tumour to the peritoneum outside of the 
pelvis and/or metastasis to the retroperitoneal lymph 
nodes (stage III), or the confirmation of distant 
metastasis excluding peritoneal metastases (stage 
IV) (Prat and FIGO Committee on Gynecologic 
Oncology, 2014).Ovarian cancer cells may spread 
to the adjacent genital organs, pelvic peritoneum, 
pelvic and para-aortic lymph nodes, omentum, 
organ, and peritoneal surfaces in the upper abdomen 
and thoracic pleura (Vergote et al., 2016a).
Genetic testing
Germline or somatic mutations in arrays of genes 
coding for proteins involved in the homologous 
recombination (HR) repair of double-strand DNA 
breaks occur in up to 40–50% of patients with HGSC 
and more rarely in the other epithelial subtypes 
(Press et al., 2008; Bell et al., 2011). The most 
prevalent among these are mutations in the breast 
cancer susceptibility genes (BRCA1/2), which are 
clinically validated to be of high value for predictive 
counselling (if germline), in particular for lifesaving 
preventive strategies in pre-symptomatic mutation 
carriers in the family. Indeed, while BRCA1/2 
somatic mutations are only found in neoplastic tissue 
and are thus not passed on to the offspring, germline 
mutations may be transmitted from parents to their 
children (Griffiths, 2000).
The homologous recombination deficiency 
(HRD) diagnosis also has prognostic and therapeutic 
implications. ABRCA-mutated ovarian cancer 
has a better prognosis and an increased platinum 
sensitivity compared to a BRCA-wildtype cancer 
(Yang et al., 2011). Moreover, in BRCA-mutated 
ovarian cancer, platinum sensitivity can be preserved 
over many treatment lines in relapsing patients. 
BRCA1/2 mutations are synthetically lethal with 
the inhibition of the poly (ADP-ribose) polymerase 
(PARP) enzyme: cells harbouring a BRCA loss of 
function undergo cell death upon PARP inhibition 
due to an excessive accumulation of unrepaired DNA 
strand breaks. In normal conditions, the HR and non-
homologous end joining (NHEJ) mechanisms repair 
these breaks (Faraoni and Graziani, 2018). In patients 
with a BRCA1/2 gene mutational loss-of-function, 
only the error-prone NHEJ can (incompletely) 
repair these breaks, resulting in the accumulation of 
DNA breaks and mutations that lead to cell death by 
synthetic lethality (Faraoni and Graziani, 2018).
Therefore, the identification of somatic and 
germline mutations in the BRCA1 and BRCA2 
genes (and other HR genes conferring sensitivity to 
PARP inhibitors [PARPis]) has become an essential 
guide for treatment decisions (Faraoni and Graziani, 
2018).
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fallopian tube cancer and with peritoneal cancer, 
ideally at diagnosis (Personalised Medicine 
Commission, 2019a; Personalised Medicine 
Commission, 2019b). NGS testing of the mutational 
BRCA1/2 status is recommended on both tumour 
DNA and germline DNA (peripheral blood cells), 
given that most of the BRCA1/2 mutations detected 
in tumours are germline (Gadducci et al., 2019; 
Personalised Medicine Commission, 2019b). In 
patients without germline or somatic BRCA1/2 
mutations in recurrence setting, the Personalised 
Medicine Commission recommends testing the other 
HRD and other ovarian cancer risk genes to identify 
patients eligible for clinical trials and cancer genetic 
counselling in the relatives. An optimal molecular 
test for comprehensively detecting the HRD status 
of cancers still needs to be defined (Personalised 
Medicine Commission, 2019a; Personalised 
Medicine Commission, 2019b).
The implementation of early systematic germline 
testing in ovarian cancer requires workflow changes 
Among other techniques, next-generation 
sequencing (NGS) of germline DNA can be used 
to identify mutations in genes associated with 
hereditary cancer risk, not only HR genes (Price 
et al., 2018). A typical panel of such genes are 
BRCA1/2, mutLhomologue 1 (MLH1), mutS 
homologue 2 (MSH2), mutS homologue 6 (MSH6), 
PMS1 homologue 2, mismatch repair system 
component (PMS2), epithelial cell adhesion 
molecule (EPCAM), tumour protein p53 (TP53), 
phosphatase and tensin homologue (PTEN) and 
serine/threonine kinase 11 (STK11) (Weissman et 
al., 2012; Silva et al., 2014; Minion et al., 2015). 
Rarely mutated ovarian cancer predisposing HR 
genes (PALB2, BRIP1, RAD51C, RAD51D, and 
BARD1) are also often included in germline panel 
testing (Norquist et al., 2016).
In Belgium, the Personalised Medicine 
Commission (ComPerMed) recommends genetic 
testing for all patients with invasive EOC (excluding 
borderline or mucinous ovarian cancers), with 
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MMR deficiency - - Yes Yes -
AKT: AKT serine/threonine kinase 1; ARIDA: AT-Rich Interaction Domain 1A; BRAF: carcinoma B-Raf proto-oncogene, serine/
threonine kinase; BRCA1/2: breast cancer 1/2 gene; CDK12: cyclin dependent kinase 12; CNA: copy number alteration; CTNNB1: 
catenin beta 1; EOC: epithelial ovarian cancer; HER2: human epidermal growth factor receptor 2; HRD: homologous recombina-
tion deficiency; KRAS: Kirsten rat sarcoma viral oncogene homologue; MAPK: mitogen-activated protein kinase; MMR: mismatch 
repair; NRAS: neuroblastoma RAS viral (V-ras) oncogene homologue; OR: oestrogen receptor; PI3K(CA): phosphoinositide-3-ki-
nase (catalytic, α polypeptide); PPP2R1α: protein phosphatase 2, subunit A, α isoform; PR: progesterone receptor; PTEN: phos-
phatase and tensin homologue; RTK: receptor tyrosine kinase; TP53: tumour protein p53; Wnt: wingless-related integration site. 
Adapted from Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medi-
cine. CA: A Cancer Journal for Clinicians. 2019;69(4):280-304; distributed under a CC BY-NC 4.0 license [https://doi.org/10.3322/
caac.21559]).
Table I.  – Subtypes of epithelial ovarian cancer: histological, molecular and gene mutation characteristics (adapted from Lheureux et 
al., CA Cancer J Clin 2019;69:280-304).
230 Facts Views Vis Obgyn
in health care practices. While current standard 
clinical practice in many countries implies a pre-
test consultation with a qualified geneticist and 
subsequent BRCA1/2 mutation status testing 
(Capoluongo, 2016), it has been recently proposed 
that trained specialised staff at oncology units should 
be enabled to perform the intake and pre-test genetic 
counselling (Capoluongo, 2016; Capoluongo et al., 
2017). One way to guarantee 100% test rates for all 
patients with ovarian cancer upon diagnosis would 
be to use “reflex” (i.e., guaranteed) tumour BRCA1/2 
mutation testing as part of the pathology department 
work-up (Hoskins, 2018). This reflex testing 
requires informed consent that informs the patient 
on the possibility of finding germline mutations. 
With this adapted approach, and if turnaround time 
can be reduced to a maximum of three weeks, delays 
in proposing personalised treatment schedules could 
be avoided. If the test detects a potential germline 
mutation, the patient should be referred to a cancer 
geneticist for further counselling (Vergote et al., 
2016b). As laparoscopic and surgical samples might 
be rapidly depleted and sufficient tissue is required 
to ensure good quality of testing, it remains key to 
maximally use the specimens (Aisner et al., 2016).
Treatment landscape 
Fundamental principles of treatment for women with 
ovarian cancer include surgery to reduce the tumour 
bulk to no residual disease whenever possible and 
appropriate systemic treatment based on the ovarian 
cancer subtype, disease stage, biology, and patient 
characteristics (Lheureux et al., 2019).
Surgery
First-line
Primary debulking surgery, which aims at complete 
resection (i.e., no residual disease), is a cornerstone 
of ovarian cancer therapy (Lheureux et al., 2019). 
Optimal primary debulking surgery is significantly 
associated with prolonged survival (Dogan et al., 
2013). Primary surgery is also indispensable for 
accurate staging of ovarian cancer according to the 
FIGO and TNM systems (Prat and FIGO Committee 
on Gynecologic Oncology, 2014).The primary 
surgical procedure comprises an exploration of the 
abdomen and pelvis, which is usually followed by a 
total abdominal hysterectomy, a bilateral salpingo-
oophorectomy, and an omentectomy in case of total 
respectability (Lheureux et al., 2019).
In women with  poor general health, a high 
perioperative risk profile, or a low likelihood 
of achieving effective cytoreduction because of 
extensive disease (advanced stages), neo-adjuvant 
chemotherapy to reduce the tumour burden should 
precede surgery (Lheureux et al., 2019). The neo-
adjuvant chemotherapy should be followed by 
interval debulking surgery when complete resection 
or effective reduction to < 1cm disease is achievable 
(Lheureux et al., 2019). A recent pooled analysis of 
the long-term follow-ups of two randomised trials 
has validated this strategy in patients with a high 
tumour burden at presentation or poor performance 
status (Vergote et al., 2018).
Recurrence
In women with recurrent ovarian cancer, the benefit 
of secondary cytoreductive surgery depends on the 
patient population; its role remains controversial 
and may depend on the systemic treatment given 
(Dogan et al., 2013). In the recent Gynaecologic 
Oncology Group (GOG) 0213 study, secondary 
surgical cytoreduction followed by platinum-
based chemotherapy did not result in longer overall 
survival (OS) than chemotherapy alone in patients 
with platinum-sensitive recurrent ovarian cancer 
(Coleman et al., 2019b). In this study, 84% of 
patients received platinum-based chemotherapy 
with bevacizumab followed by bevacizumab 
maintenance. In contrast, interim findings from 
the ongoing third Descriptive Evaluation of 
preoperative Selection KriTeria for OPerability 
in recurrent ovarian cancer (DESKTOP III) study 
showed that secondary surgical cytoreduction 
resulted in clinically meaningful increases of 
progression-free survival (PFS) and median time 
to start the first subsequent therapy in patients 
with a first relapse of ovarian cancer and a positive 
German Gynaecological Oncology Group (AGO) 
score (Performance Status Eastern Cooperative 
Oncology Group [PS ECOG] 0, ascites ≤500 ml, 
and complete resection at initial surgery) (Du Bois 
et al., 2017).Findings from these two studies suggest 
that secondary cytoreductive surgery may only be 
beneficial for patients with platinum-sensitive 
recurrence when complete resection is achievable 
(Du Bois et al., 2017; Bommert et al., 2018).
Systemic treatments
First-line
The current standard first-line systemic treatment, 
administered after primary debulking surgery 
or as neoadjuvant therapy is a platinum-based 
doublet intravenous chemotherapy (carboplatin 
and paclitaxel, every 3 weeks, or carboplatin every 
3 weeks and paclitaxel weekly) with bevacizumab 
(Lheureux et al., 2019).
In case of intolerance to paclitaxel, alternative 
platinum-based doublet regimens are carboplatin 
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treatment of platinum-sensitive relapsed ovarian 
cancer (European Medicines Agency). Another 
recent study showed a clinically relevant survival 
benefit in platinum-sensitive patients with germline 
BRCA1/2 mutations who were treated in third-
line with the association of trabectedin plus PLD 
compared to PLD alone (Monk et al., 2020).
Targeted and antiangiogenic agents
Treatment of first-line and recurrent ovarian 
cancer has now expanded to include targeted and 
antiangiogenic agents (Lheureux et al., 2019).The 
targeted agents approved by the EMA include 
three PARPis (olaparib, niraparib and conditional 
approval for rucaparib) (European Medicines 
Agency, 2019a; European Medicines Agency, 
2019b; European Medicines Agency, 2019c). In 
addition, one antiangiogenic agent (bevacizumab) 
is also approved by the EMA (European Medicines 
Agency, 2019d). Pivotal trials evaluating their use 
in first- and further-line treatment are detailed in 
Tables II and III.
In Europe, olaparib, niraparib and rucaparib 
are indicated as monotherapy for the maintenance 
treatment of adult patients with platinum-sensitive, 
relapsed, high-grade, serous epithelial ovarian, 
fallopian tube, or primary peritoneal cancer (BRCA-
mutated for olaparib) who are in response to 
platinum-based chemotherapy (European Medicines 
Agency, 2019a; European Medicines Agency, 
2019b; European Medicines Agency, 2019c). 
Rucaparib is also indicated as a monotherapy 
treatment of adult patients with platinum-sensitive, 
relapsed or progressive, BRCA-mutated, high-
grade, epithelial ovarian, fallopian tube, or primary 
peritoneal cancer who have been treated with at least 
two prior lines of platinum-based chemotherapy 
and are unable to tolerate further platinum-based 
chemotherapy (European Medicines Agency, 
2019c). In Belgium, olaparib is reimbursed as a 
single agent for maintenance treatment in patients 
with newly diagnosed, advanced ovarian cancer 
and a BRCA1/2 mutation, who have a complete or 
partial clinical response after first-line platinum-
based chemotherapy. The randomised, double-blind, 
phase III trial (SOLO1 study) has shown that the 
use of maintenance therapy with olaparib compared 
with placebo provides a substantial benefit with 
regard to PFS in this population (Table II) (Moore 
et al., 2018).
Moreover, olaparib is reimbursed in Belgium as 
a single agent for maintenance treatment in patients 
with recurrent platinum-sensitive, PARP-naïve, 
BRCA-mutated, high-grade EOC, fallopian tube 
cancer or primary peritoneal cancer after at least 
two prior lines of platinum-based chemotherapy 
with docetaxel or with pegylated liposomal 
doxorubicin (PLD),which should be used according 
to the patient’s/physician’s treatment preferences 
and the patient-specific drug tolerability since each 
of the regimens is associated with a specific toxicity 
profile (Katsumata, 2003; Pignata et al., 2011).The 
carboplatin with PLD regimen is not reimbursed in 
Belgium in first-line. 
Recurrence
Although surgical resection followed by first-line 
platinum-based chemotherapy leads to complete 
remission in many patients, recurrences occur in 
up to 70% of cases (Dogan et al., 2013).Although 
the recurrent disease is incurable, treatments in this 
setting have the intention of controlling the symptoms 
and the disease, to maintain the quality of life, and to 
prolong the treatment-free periods. Depending on the 
duration of the treatment-free interval before disease 
recurrence, patients are classically categorised into 
“platinum-sensitive”(relapse ≥ six months since 
last platinum-based treatment) versus “platinum-
resistant” (relapse < six months since last platinum-
based treatment) (Buechel et al., 2019). Given the 
advances in ovarian cancer surveillance allowing for 
faster detection of relapse, the lack of consensus 
on how progression is defined, and the emergence 
of other first-line therapies, new guidelines do not 
adopt such a stringent six-month limit for defining 
platinum-sensitive patients (Buechel et al., 2019). 
Also, more patients may be incorrectly excluded 
from platinum-based regimens in the future as 
recurrences will be detected earlier (Buechel et al., 
2019).
The management of recurrent ovarian cancer is 
less validated than that of newly diagnosed ovarian 
cancer (Dogan et al., 2013).After recurrence, 
platinum-resistant patients should receive non-
platinum-based single-agent chemotherapy (PLD, 
paclitaxel, topotecan or gemcitabine) (Ledermann 
et al., 2018).In contrast, platinum-sensitive patients 
may be re-challenged with platinum-based doublet 
chemotherapy (Ledermann et al., 2018; Lheureux 
et al., 2019). The intercalation of a non-platinum 
regimen could confer a clinically meaningful benefit 
to some patients with platinum-sensitive relapsed 
ovarian cancer and give them time to recover 
from platinum-related toxicities (Colombo, 2017; 
Romero et al., 2019). A randomised phase III study 
(ET743-OVA-301) demonstrated improved efficacy 
with an acceptable tolerance of the association of 
trabectedin (an antineoplastic agent) plus PLD 
versus PLD alone in patients with platinum-
sensitive relapsed ovarian cancer (Monk et al., 
2010), leading to the approval of this association 
by the European Medicines Agency (EMA) for the 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table II.  – Pivotal clinical trials of first-line treatment with targeted agents in ovarian cancer patients.
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Table III.  – Pivotal clinical trials of second-line treatment with targeted agents in ovarian cancer patients.





























































































































































































































































































































































































































































































































































































































































































































































































































































































Table III.  – Continued.
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Figure 1: Treatment algorithm for epithelial ovarian cancer.
+/-: with/without; debulking: complete resection (i.e., residual disease=0 cm); BRCA: breast cancer gene; PARPi: 
poly (ADP-ribose) polymerase inhibitor; PFI: platinum-free interval until relapse; PLD: pegylated liposomal 
doxorubicin.1The goal is complete resection, but surgery is sometimes indicated if only effective cytoreduction 
(<1 cm of residual disease) is achievable. 2If intolerance to paclitaxel, alternative regimens should be used ac-
cording to preference and tolerability (carboplatin + docetaxel or carboplatin + PLD). 3Olaparib, niraparib and 
rucaparib (niraparib and rucaparib are not reimbursed in Belgium yet). 4In Europe, only rucaparib is licensed by 
the European Medicines Agencyas a monotherapy for patients with platinum-sensitive disease. 5For patients who 
have not received prior therapy with a vascular endothelial growth factor receptor-targeted agent. 6Participation 
in clinical trials is in all steps of the flowchart an option.
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treatment approaches in ovarian cancer. Based 
on recent results, infrastructural and pragmatic 
workflow changes are necessary to implement early 
systematic genetic testing and counselling, and to 
timely plan the integration of targeted agents and 
antiangiogenic agents, which have now proven 
their efficacy in clinical practice, into treatment 
strategies. Since new treatments for ovarian cancer 
are currently under development and should be 
implemented in the coming years, ongoing research 
should further help refine the precise treatment 
algorithm and answer open questions in this rapidly 
evolving field.
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(Specenier, 2016). Niraparib and rucaparib are not 
yet reimbursed for that indication.
Bevacizumab is indicated and reimbursed in 
Belgium in combination with carboplatin and 
paclitaxel for the first-line treatment of adult 
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